Literature DB >> 34661061

Targeting the cancer neoantigens p53 and KRAS with TCR mimic antibodies.

Zhijian Duan1, Mitchell Ho1,2.   

Abstract

Entities:  

Keywords:  TCR mimic antibody; bispecific antibody or bsAb; cancer immunotherapy; neoantigen; single chain diabody or scDb

Year:  2021        PMID： 34661061      PMCID： PMC8515948          DOI： 10.1093/abt/tbab021

Source DB:  PubMed          Journal:  Antib Ther        ISSN： 2516-4236


× No keyword cloud information.
  10 in total

Review 1.  Alternative molecular formats and therapeutic applications for bispecific antibodies.

Authors:  Christoph Spiess; Qianting Zhai; Paul J Carter
Journal:  Mol Immunol       Date:  2015-01-27       Impact factor: 4.407

Review 2.  Cancer Neoantigens.

Authors:  Ton N Schumacher; Wouter Scheper; Pia Kvistborg
Journal:  Annu Rev Immunol       Date:  2018-12-14       Impact factor: 28.527

3.  Introduction to checkpoint inhibitors and cancer immunotherapy.

Authors:  Arlene H Sharpe
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

4.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Authors:  Boris Engels; Victor H Engelhard; John Sidney; Alessandro Sette; David C Binder; Rebecca B Liu; David M Kranz; Stephen C Meredith; Donald A Rowley; Hans Schreiber
Journal:  Cancer Cell       Date:  2013-04-15       Impact factor: 31.743

5.  Bispecific antibodies targeting mutant RAS neoantigens.

Authors:  Jacqueline Douglass; Emily Han-Chung Hsiue; Brian J Mog; Michael S Hwang; Sarah R DiNapoli; Alexander H Pearlman; Michelle S Miller; Katharine M Wright; P Aitana Azurmendi; Qing Wang; Suman Paul; Annika Schaefer; Andrew D Skora; Marco Dal Molin; Maximilian F Konig; Qiang Liu; Evangeline Watson; Yana Li; Michael B Murphy; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Sandra B Gabelli; Kenneth W Kinzler; Bert Vogelstein; Shibin Zhou
Journal:  Sci Immunol       Date:  2021-03-01

6.  Targeting a neoantigen derived from a common TP53 mutation.

Authors:  Emily Han-Chung Hsiue; Katharine M Wright; Jacqueline Douglass; Michael S Hwang; Brian J Mog; Alexander H Pearlman; Suman Paul; Sarah R DiNapoli; Maximilian F Konig; Qing Wang; Annika Schaefer; Michelle S Miller; Andrew D Skora; P Aitana Azurmendi; Michael B Murphy; Qiang Liu; Evangeline Watson; Yana Li; Drew M Pardoll; Chetan Bettegowda; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; Shibin Zhou
Journal:  Science       Date:  2021-03-01       Impact factor: 47.728

7.  An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules.

Authors:  Jane Harper; Katherine J Adams; Giovanna Bossi; Debbie E Wright; Andrea R Stacey; Nicole Bedke; Ruth Martinez-Hague; Dan Blat; Laure Humbert; Hazel Buchanan; Gabrielle S Le Provost; Zoe Donnellan; Ricardo J Carreira; Samantha J Paston; Luise U Weigand; Martina Canestraro; Joseph P Sanderson; Sophie Botta Gordon-Smith; Kate L Lowe; Karolina A Rygiel; Alex S Powlesland; Annelise Vuidepot; Namir J Hassan; Brian J Cameron; Bent K Jakobsen; Joseph Dukes
Journal:  PLoS One       Date:  2018-10-15       Impact factor: 3.240

Review 8.  Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life.

Authors:  Kevin O Saunders
Journal:  Front Immunol       Date:  2019-06-07       Impact factor: 7.561

9.  Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.

Authors:  Nathan D Trinklein; Duy Pham; Ute Schellenberger; Ben Buelow; Andrew Boudreau; Priya Choudhry; Starlynn C Clarke; Kevin Dang; Katherine E Harris; Suhasini Iyer; Brett Jorgensen; Payal P Pratap; Udaya S Rangaswamy; Harshad S Ugamraj; Omid Vafa; Arun P Wiita; Wim van Schooten; Roland Buelow; Shelley Force Aldred
Journal:  MAbs       Date:  2019-02-20       Impact factor: 5.857

Review 10.  T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy.

Authors:  Zhijian Duan; Mitchell Ho
Journal:  Mol Cancer Ther       Date:  2021-06-25       Impact factor: 6.009
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.